Most of the recent buzz in metabolic drug development has centered on GLP-1 and dual GLP-1/GIP agonists. Eli Lilly's eloralintide takes a different route entirely, targeting the amylin pathway instead, and its Phase 2 results, announced in November 2025, are notable enough that the company is now moving toward Phase 3.
What Eloralintide Is
Eloralintide is a selective amylin receptor agonist. Amylin is a hormone released by the pancreas alongside insulin that plays a role in appetite regulation and satiety through a different receptor pathway than GLP-1. Unlike tirzepatide, which combines GIP and GLP-1 receptor activity, or cagrilintide, which is an amylin analog typically studied in combination with a GLP-1 drug, eloralintide is being developed and was tested in this trial as a monotherapy, acting on the amylin pathway on its own.
What the Phase 2 Trial Found
Eli Lilly's Phase 2 study enrolled 263 adults with obesity or overweight and tested a range of doses against placebo. The company reported dose-dependent weight loss: 9.5% at the 1 mg dose, 12.4% at 3 mg, 17.6% at 6 mg, and 20.1% at the highest 9 mg dose, compared with 0.4% in the placebo group. Lilly described the most common side effects as mild to moderate gastrointestinal symptoms and fatigue, occurring more frequently at higher doses, with lower-dose arms showing tolerability closer to placebo.
Why a Monotherapy Amylin Drug Is Interesting
Amylin agonists have historically been studied as an add-on to GLP-1 therapy rather than a replacement for it, partly because amylin's effects on satiety are considered complementary to, rather than a substitute for, GLP-1's effects on appetite and gastric emptying. A monotherapy amylin drug that can produce weight loss in this range on its own is a meaningful data point for the field, because it suggests the amylin pathway alone may be more potent than previously assumed, and it raises the possibility of combination regimens that pair amylin and GLP-1 mechanisms for effects beyond what either produces individually.
Regulatory Status
Eloralintide is not FDA-approved. It remains an investigational drug. Lilly stated it plans to begin Phase 3 clinical trials of eloralintide as a monotherapy for obesity, and the company is separately evaluating its potential as a complementary option alongside incretin therapies like tirzepatide. Phase 3 trials, if they proceed and succeed, would still need to be followed by an FDA regulatory submission and review before any approval, a process that typically takes years from this stage.
How This Fits Into the Broader Pipeline
Eloralintide joins a growing list of amylin-focused candidates in development, including cagrilintide, which Novo Nordisk has studied both alone and paired with semaglutide in the combination sometimes called CagriSema. The interest in amylin reflects a broader trend in obesity drug development: after several years of GLP-1 and GLP-1/GIP dominance, companies are now exploring additional hormonal pathways, partly to improve efficacy and partly in response to concerns, discussed elsewhere on this site, about the proportion of lean mass lost alongside fat during GLP-1-driven weight loss.
The Bottom Line
A 20.1% average weight loss in a mid-stage trial is a genuinely strong result for an amylin-only approach, but it comes from a single Phase 2 study of 263 people, not the larger, longer trials that will be needed to establish a durable safety and efficacy profile. Phase 2 results, even encouraging ones, fail to become approved drugs more often than they succeed, and eloralintide is still several trial phases and years away from any possible approval.
Talk to Your Doctor
Eloralintide is not available for human use outside of clinical trials. If you are interested in participating in obesity drug research, or in understanding how an investigational drug like this might eventually fit into your own treatment options, that conversation belongs with a licensed physician, not with this article.